Phentolamine: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - "α 1" to "α<sub>1</sub>") |
(Switch SMW query from broadtable to table format for better layout with TOC) |
||
| (5 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: [[ | *Type: [[Alpha 1 Blocker]]; [[Antidote]], Extravasation; [[Antihypertensive]] | ||
*Routes of Administration: IV, IM | *Routes of Administration: IV, IM | ||
*Common Trade Names: OraVerse | *Common Trade Names: OraVerse | ||
| Line 29: | Line 29: | ||
*Hypersensitivity to phentolamine or components | *Hypersensitivity to phentolamine or components | ||
*[[MI]] | *[[MI]] | ||
* | *CAD | ||
*Angina | *Angina | ||
*Caution if PUD | *Caution if PUD | ||
| Line 59: | Line 59: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*[[α antagonist]] | *[[alpha 1 Blocker|α antagonist]] | ||
==Indications by Condition== | |||
''The following table is automatically generated from disease/condition pages across WikEM.'' | |||
{{#ask:[[Has DrugName::Phentolamine]] | |||
|?Has Indication=Indication | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|?Has Route=Route | |||
|?Has Population=Population | |||
|format=table | |||
|headers=plain | |||
|mainlabel=- | |||
|sort=Has Indication | |||
|limit=50 | |||
}} | |||
==See Also== | |||
*[[Vasopressors]] | |||
==References== | ==References== | ||
<Epocrates, UpToDate> | <Epocrates, UpToDate> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
Latest revision as of 21:56, 20 March 2026
Administration
- Type: Alpha 1 Blocker; Antidote, Extravasation; Antihypertensive
- Routes of Administration: IV, IM
- Common Trade Names: OraVerse
Adult Dosing
- Pheochromocytomectomy adjunct: 5mg IM/IV q2-4h PRN
- Start: 1-2h preop
- Extravasation (norepinephrine-associated): 5-10mg injected into affected area x1
- Start: within 12h of extravasation
- Hypertensive crisis: 5mg IM/IV q2-4h PRN
Pediatric Dosing
- Pheochromocytomectomy adjunct: 1mg IM/IV q2-4h PRN
- Start: 1-2h preop
Special Populations
- Pregnancy Risk Factor: C
Renal Dosing
- No dosing adjustments
Hepatic Dosing
- No dosing adjustments
Contraindications
- Hypersensitivity to phentolamine or components
- MI
- CAD
- Angina
- Caution if PUD
Adverse Reactions
Serious
- MI
- stroke
- hypotension, severe
- arrhythmias
- PUD
- priapism
Common
- tachycardia
- weakness
- dizziness
- flushing
- orthostatic hypotension
- nasal congestion
- nausea
- vomiting
- diarrhea
Pharmacology
- Half-life: 19 minutes
- Metabolism: Urine
- Excretion: CYP450
Mechanism of Action
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Cocaine toxicity | 2.5-5mg IV | Direct alpha-antagonist for refractory hypertension | IV | Adult |
| Hypertensive emergency | 5-15 mg IV | Pheochromocytoma crisis | IV | Adult |
| Monoamine oxidase inhibitor toxicity | 2.5-5mg IV bolus q10-15min; or infusion 0.2-0.5mg/min | Hypertension, short-acting agent | IV | Adult |
| Pheochromocytoma | 5 mg q2-4hr PRN | Alpha-blocker for hypertensive crisis | IV/IM | Adult |
See Also
References
<Epocrates, UpToDate>